At a price that is one-third less than the innovator brand, BDR Pharmaceutical introduced the first generic version of the important prostate cancer medication apalutamide under the trade name Apatide in India.
Raheel Shah, Director Business Development, BDR Group said that the product will be available across India in strengths of 60mg in packs of 60 tablets and 120 tablets. “Typically a patient is put on this drug for two months with a gap of one week in between the two months,” Shah said.
The price for a bottle of 60 tablets is Rs 22,500 and for a bottle of 120 tablets is Rs 45,000
The University of California system invented apalutamide, which was principally developed by Janssen Research & Development, a unit of Johnson & Johnson.
"Apalutamide will greatly increase patients with metastatic castration-sensitive prostate cancer's odds of survival when used in conjunction with anti-androgen therapy. In non-metastatic castration-resistant prostate cancer, the combination of apalutamide and ADT (androgen-deprivation therapy) significantly lowers the risk of disease progression and mortality, according to the company.
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
By 2030, the burden of prostate cancer is projected to increase to 1.7 million new cases and 4, 99,000 new deaths worldwide due only to population growth and ageing. Prostate cancer is the sixth most common cause of cancer deaths among males worldwide and the second most common malignancy in India. With no acceptances, information about the illness is only minimally accessible to people.